Matthew M. Girgenti
Subscribe to Matthew M. Girgenti's PostsMatthew M. Girgenti focuses his practice on complex civil litigation and government investigations. He has experience in a broad range of litigation matters, including
Fifth Amendment takings claims against the federal government
Contract and tort disputes between commercial entities
Americans with Disabilities Act claims defense
False Claims Act litigation
Administrative, state and federal motion and appellate practice
Read Matthew Girgenti's full bio.
Health Care Enforcement Quarterly Roundup – Q1 2019
By McDermott Will & Emery, Amandeep S. Sidhu, Drew Elizabeth McCormick, Irene A. Firippis, James A. Cannatti III, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti, Paul M. Thompson, Sean Hennessy, Sophia A. Luby, Theodore Alexander, Tony Maida and T. Reed Stephens on Apr 26, 2019
Posted In Additional Compliance Resources, Other Notable Enforcement Actions, Pharmaceuticals
In this first installment of the Health Care Enforcement Quarterly Roundup for 2019, we continue to monitor trends we identified in 2018 and introduce new enforcement efforts that are expected to persist in the coming year. In this Roundup, we focus on increased enforcement activity against electronic health record (EHR) companies, enforcement against individuals (with an acute focus...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q4 2018
By Sophia A. Luby, Theodore Alexander, Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amandeep S. Sidhu, Irene A. Firippis, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti, Natalie Colvin and Paul M. Thompson on Jan 30, 2019
Posted In Compliance Developments, Other Notable Enforcement Actions, Yates Memorandum
This latest installment of the Health Care Enforcement Quarterly Roundup reflects on trends that persisted in 2018 and those emerging trends that will carry us into 2019 and beyond. Leading off with the US Department of Justice’s (DOJ) December announcement of its fiscal year 2018 False Claims Act (FCA) recoveries, it remains clear that the...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q3 | September 2018
By Paul M. Thompson, Sophia A. Luby, Theodore Alexander, Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amy H. Kearbey, Amandeep S. Sidhu, Irene A. Firippis, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti and Natalie Colvin on Oct 8, 2018
Posted In Compliance Developments, Other Notable Enforcement Actions
In the latest installment of Health Care Enforcement Quarterly Roundup, we examine key enforcement trends in the health care industry that we have observed over the past few months. In this issue, we report on: Practical applications of recent guidance from the US Department of Justice (DOJ) A recent blow to DOJ’s effort to use...
Continue Reading
Insys Announces Settlement-in-Principle with DOJ Over Alleged Subsys Kickback Scheme
By Amandeep S. Sidhu and Matthew M. Girgenti on Sep 13, 2018
Posted In Anti-Kickback Statute / Stark Law, Government investigation, Other Notable Enforcement Actions, Pharmaceuticals, State Law Claims, Yates Memorandum
Last month, Insys Therapeutics, Inc. announced that it reached a settlement-in-principle with the U.S. Department of Justice (DOJ) to settle claims that it knowingly offered and paid kickbacks to induce physicians and nurse practitioners to prescribe the drug Subsys and that it knowingly caused Medicare and other federal health care programs to pay for non-covered...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q2 | July 2018
By Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amandeep S. Sidhu, David S. Rosenbloom, Emily J. Cook, Laura McLane, Matthew M. Girgenti, Monica Wallace, Natalie Colvin, Paul M. Thompson, Sandra M. DiVarco, Stephen W. Bernstein and Sophia A. Luby on Jul 18, 2018
Posted In Compliance Developments, Other Notable Enforcement Actions
How will key trends and developments in health care policy and enforcement impact future litigants? In the latest Health Care Enforcement Quarterly Roundup, we address this question in the context of: Continued interpretations of the landmark Escobar case The latest guidance from US Department of Justice (DOJ) leadership regarding enforcement priorities The uptick in state...
Continue Reading
New DOJ Task Force to Take on Opioid Crisis Using the FCA and Other Enforcement Tools
By Amandeep S. Sidhu, Matthew M. Girgenti and Paul M. Thompson on Mar 2, 2018
Posted In Additional Compliance Resources, Compliance Developments, Government investigation, Other Notable Enforcement Actions, Pharmaceuticals
Earlier this week, the US Department of Justice (DOJ) launched a new front in its effort to combat the opioid crisis and explicitly stated that it will deploy the False Claims Act (FCA) as part of its offensive. In a press release and parallel speech delivered by Attorney General Jeff Sessions on February 28, 2018,...
Continue Reading
